Blood-Brain Barrier Penetration of Therapeutic Agents in Human
Status:
Completed
Trial end date:
2021-02-23
Target enrollment:
Participant gender:
Summary
This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed
at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o.
doses of ODM-104 for 5-7 days. Single dose of paracetamol will be administered p.o. together
with ODM-104 for purposes of comparison.